Celon Pharma S.A. is an integrated pharmaceutical company which conducts advanced research and manufactures modern drugs. The company is also a successful marketing authorisation holder for it products. The drugs we offer help thousands of patients lead a better and longer life.
- Current report 42/2021 – Registration of D-series shares with the KDPWThe Management Board of Celon Pharma S.A. (the “Company”) hereby announces that it was informed of the publication of an announcement by Krajowy Depozyt Papierów Wartościowych S.A. on the registration in the securities depository of 6,000,000 of the Company's ordinary D-series bearer shares under ISIN PLCLNPH00015 code on September 22, 2021
- Current report 41/2021 – Supplement to Current Report No 35/2021 on the summary of subscription of ordinary D-series bearer shares of Celon Pharma S.A.The Management Board of Celon Pharma S.A. (the “Company”) hereby publishes a supplement to current report No. 35/2021 dated July 29, 2021 regarding the costs related to the subscription of the Company's ordinary D-series bearer shares (D-series Shares) referred to in items 12 and 13 of the aforementioned current report:
- Current report 40/2021 – Admission and introduction of ordinary D-series bearer shares of the Company to stock exchange tradingThe Management Board of Celon Pharma S.A. (the “Company”) hereby announces that on 15 September 2021 the Management Board of the Warsaw Stock Exchange (“GPW”) has adopted a resolution concerning the admission and introduction of the Company’s ordinary D-series bearer shares to stock exchange trading on the GPW Main Market List.
Research and development
We create innovative drugs, that will change the lives of patients globally
We are leaders in